Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDJRU1)

Drug Name

MM-121 Drug Info

Synonyms

SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2	[2]

Cross-matching ID

TTD Drug ID: DMDJRU1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erbb3 tyrosine kinase receptor (Erbb-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[4]
MEHD-7945A	DMHOF7T	Colorectal cancer	2B91.Z	Phase 2	[5]
Seribantumab	DMYT470	Colorectal cancer	2B91.Z	Phase 2	[6]
CDX-3379	DM5GKYD	Squamous cell carcinoma	2B60-2D01	Phase 2	[6]
Elisidepsin	DMB38KH	Psoriasis vulgaris	EA90	Phase 2	[7]
Zenocutuzumab	DM1FLHH	Pancreatic cancer	2C10	Phase 2	[8]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[2]
Zenocutuzomab	DMMQGPE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
LJM716	DMGTB5N	Breast cancer	2C60-2C65	Phase 1/2	[10]
AMG888/U3-1287	DMEF4L5	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb3 tyrosine kinase receptor (Erbb-3)	TTDC8N2	ERBB3_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Company report (Merrimack)
4	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
5	Company report (Biooncology)
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
8	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
9	Clinical pipeline report, company report or official report of Merus.
10	An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).